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Nucleoside analogs are important in the treatment of
hematologic malignancies, solid tumors, and viral infec-
tions. Their metabolism to the triphosphate form is cen-
tral to their chemotherapeutic efficacy. Although the
nucleoside kinases responsible for the phosphorylation
of these compounds have been well described, the nucle-
otidases that may mediate drug resistance through de-
phosphorylation remain obscure. We have cloned and
characterized a novel human cytosolic 5*-nucleotidase
(cN-I) that potentially may have an important role in
nucleoside analog metabolism. It is expressed at a high
level in skeletal and heart muscle, at an intermediate
level in pancreas and brain, and at a low level in kidney,
testis, and uterus. The recombinant cN-I showed high
affinity toward dCMP and lower affinity toward AMP
and IMP. ADP was necessary for maximal catalytic ac-
tivity. Expression of cN-I in Jurkat and HEK 293 cells
conferred resistance to 2-chloro-2*-deoxyadenosine,
with a 49-fold increase in the IC50 in HEK 293 and a
greater than 400-fold increase in the IC50 in Jurkat cells.
Expression of cN-I also conferred a 22-fold increase in
the IC50 to 2*,3*-difluorodeoxycytidine in HEK 293 cells
and an 82-fold increase in the IC50 to 2*,3*-dideoxycyti-
dine in Jurkat cells. These data indicate that cN-I may
play an important role in the regulation of physiological
pyrimidine nucleotide pools and may also alter the ther-
apeutic efficacy of certain nucleoside analogs.
Nucleoside analogs are used as chemotherapeutic agents in
the treatment of hematologic malignancies and as anti-viral
drugs. These compounds are taken up by cells through nucle-
oside transporters in the cell membrane or, in the case of more
lipophilic drugs, through diffusion (1–3). Once in the cyto-
plasm, the nucleoside analogs are substrates for phosphoryla-
tion by the nucleoside kinases of the deoxyribonucleoside sal-
vage pathway (reviewed in Ref. 4). The enzyme 29-
deoxycytidine kinase phosphorylates dAdo, dCyd, and dGuo as
well as the analogs AraC,1 dFdC, and CdA, whereas thymidine
kinase 1 phosphorylates dThd and dUrd as well as the analogs
d4T and 5-FU. Phosphorylation to the monophosphate form is
considered the rate-limiting step of activation of nucleoside
analogs (4).
Nucleoside analog monophosphates are rapidly phosphoryl-
ated to their triphosphate forms, which are believed to mediate
their cytotoxic activities by several different mechanisms (re-
viewed in Ref. 5). For example, they can be directly incorpo-
rated into DNA, leading to chain termination, or they can
inhibit DNA synthesis by direct inhibition of DNA polymerase.
It has recently been demonstrated that certain of these metab-
olites, including CdATP, AraATP, and F-AraATP, can induce
apoptosis in nonproliferating cells by interacting with cyto-
chrome c and apoptosis protein-activating factor-1 (APAF-1) to
cleave and activate the caspases responsible for the induction
of apoptosis (6, 7). In contrast, the triphosphates of antiretro-
viral compounds, such as 29,39-dideoxycytidine (ddC) and d4T,
inhibit the reverse transcriptase of the human immunodefi-
ciency virus through chain termination. Cytotoxicity can occur
when these compounds are incorporated into nuclear or mito-
chondrial DNA (reviewed in Ref. 8).
Resistance to nucleoside analogs is a significant clinical
problem and can be caused by a number of factors affecting the
metabolism of the drugs, including decreased numbers of nu-
cleoside transporters, increased deamination of cytidine and
adenosine analogs, loss of expression of activating kinases,
modulation of the downstream apoptotic machinery, and in-
creased activity of nucleotidases that catalyze the conversion of
nucleotides back to nucleosides (reviewed in Ref. 5). The 59-
nucleotidases oppose the action of nucleoside kinases by de-
phosphorylating the monophosphate form of nucleosides and
nucleoside analogs and, therefore, are likely to be important in
determining the sizes and turnover rates of the deoxyribonu-
cleotide pools. Thus, 59-nucleotidases that catabolize the mono-
phosphates of nucleoside analogs used in the clinic will lower
their clinical efficacy.
To date, the substrate specificity of the cytosolic nucleoti-
dases responsible for dephosphorylation and inactivation of
nucleoside monophosphates has not been well defined. Among
several potentially important 59-nucleotidases, only human cy-
tosolic 59-nucleotidase II (cN-II) has been studied in detail.
cN-II is a 65-kDa protein that is strongly activated by ATP and
prefers IMP to AMP as a substrate (9–11). Although increased
expression of cN-II has been shown to lead to drug resistance in
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two cell lines (12, 13), its kinetic properties make it unlikely to
participate in pyrimidine nucleotide dephosphorylation (10).
Cytosolic 59-nucleotidase I (cN-I) has been isolated from pigeon,
rat, rabbit, dog, and human hearts (14–19). This 59-nucleotid-
ase is activated by ADP and prefers AMP to IMP as a substrate
(20). Although recent kinetic data suggest that cN-I may par-
ticipate in deoxyribonucleoside monophosphate catabolism
(17), the role of this enzyme in nucleoside analog resistance has
never been examined. Thus we hypothesize that cN-I might
play a role in dephosphorylation of deoxyribonucleoside mono-
phosphates and in inactivation of nucleoside analogs.
To determine the role of the human cN-I enzyme in normal
nucleotide metabolism as well as in drug resistance, we have
cloned the human cN-I cDNA, defined the substrate specificity
of the recombinant cN-I protein, and investigated the role of
this enzyme in nucleoside analog resistance.
EXPERIMENTAL PROCEDURES
Chemicals and Reagents
AraC, ddC, CdA, F-AraA, 5-FU, d4T, and AraCMP were purchased
from Sigma. CdAMP was manufactured by Biolog Life Science Institute
(Bremen, Germany). Compound 506U (AraG prodrug) was obtained
from Glaxo-Wellcome (Research Triangle Park, NC), dFdC was a gift
from Lilly, and F-AraAMP was obtained from Berlex (Richmond, CA).
Cloning of Human cN-I
Reverse transcription-PCR was performed using human heart
poly(A) mRNA (CLONTECH, Palo Alto, CA). Primers were designed to
overlap the 59 (TAAGCTTGGTACCATGGAACCTGGGCAGCCCCGGG-
AGCCCCAG) and 39 (CTACTGTGCAGATGGGGCCTGCTTTGC) ends
of the cDNA-coding region. The reverse transcription reaction was
performed using avian myeloblastosis virus reverse transcription (Pro-
mega, Madison, WI), the PCR reaction was performed with Pfu Turbo
(Stratagene, La Jolla, CA) in a buffer containing 10% Me2SO followed
by 10 cycles with Taq polymerase (Life Technologies, Inc.) to enable
cloning into the TA vector (Invitrogen, Carlsbad, CA), and individual
clones were sequenced.
Northern Blot Analysis
Total cellular RNA was extracted using TRI REAGENT (Molecular
Research Center, Cincinnati, OH). Fifteen mg of total RNA was loaded
on each lane and separated in 1% agarose, 100 mM MOPS buffer, and
2.0 M formaldehyde. RNA was transferred to a nylon membrane, UV-
cross-linked, and baked at 80 °C for 1 h. Blots were prehybridized in 1%
SDS, 0.1 M NaCl at room temperature for 1 h and at 42 °C in High
Efficiency Hybridization System containing 50% formamide (Molecular
Research Center, Cincinnati, OH) for 1 h. The 32P-labeled 671-base pair
probe (extending from base pair 437 to base pair 1107 of the cN-I cDNA
sequence) was then added and hybridized overnight at 42 °C. The blots
were washed for 30 min at 55 °C and for 30 min at 60 °C in 13 SSC
(0.15 M NaCl and 0.015 M sodium citrate), 0.2% SDS and autoradio-
graphed. The 32P-labeled b-actin probe was hybridized as described
above and washed twice for 15 min at room temperature in 23 SSC,
0.05% SDS and twice for 20 min at 50 °C in 0.13 SSC, 0.1% SDS.
Baculovirus Expression
cN-I was expressed in Sf9 insect cells using the baculovirus expres-
sion system (Life Technologies) according to the product protocol.
Briefly, the cN-I construct was subcloned into the PDR120 transfer
vector and transfected into DH10Bac cells. Bacmid was isolated from
DH10Bac bacterial colonies, and baculovirus was produced by infecting
Sf9 cells with bacmid DNA and harvesting virus from the media after
cell lysis. For protein purification, Sf9 cells were collected 4 days after
infection, pelleted, and frozen at 280 °C.
Purification of cN-I
Recombinant human cN-I was purified using a modification of pre-
viously published protocols for purification of the rabbit enzyme (16,
17). Sf9 cells (7.7 g) were resuspended in 40 ml of extraction buffer
containing 40 mM NaHEPES, pH 7.0, 15% glycerol, 1 mM EDTA, 1 mM
dithiothreitol, 0.2 mM phenylmethylsulfonyl fluoride, 5 mM benzami-
dine, and 13 complete protease inhibitor mixture (Roche Molecular
Biochemicals). The cells were homogenized 3 3 10 s with a tissue
homogenizer (Tekmar Tissumizer, Cincinnati, OH) and centrifuged at
16,000 3 g at 4 °C to pellet membranes. The pellet was re-homogenized,
and the supernatants were combined. cN-I was precipitated with 40%
ammonium sulfate, and the resulting pellet was solubilized in 2 ml of
extraction buffer and dialyzed against 3 changes of buffer A (40 mM
NaHEPES, pH 7.0, 15% glycerol, 1 mM EDTA, 1 mM dithiothreitol, 0.2
mM phenylmethylsulfonyl fluoride, and 5 mM MgCl2) overnight.
After dialysis the sample was rehomogenized in 11 ml of buffer A and
incubated for 1 h at 4 °C with 5 g of wet Whatman P11-cellulose
phosphate (Whatman, Kent, ME). The phosphocellulose was centri-
fuged to remove unbound proteins, resuspended in buffer A, and trans-
ferred into a column. The column was washed with 100 ml of buffer A,
and bound proteins were eluted with 100 ml each of 0.25 M NaCl, 0.4 M
NaCl, 0.6 M NaCl, and 2 M NaCl/2.1 mM sodium phosphate. Fractions
containing cN-I activity were eluted at 0.25 M NaCl and were further
concentrated to ;15 ml using an Ultrafree-15 filter with 30-kDa cut-off
range (Millipore, Bedford, MA). The sample was dialyzed overnight
against buffer A and run on a DEAE-Sepharose column with buffer A
adjusted to pH 7.5. The column was washed, and proteins were eluted
with a 0–0.5 M NaCl gradient in buffer A. The fractions containing cN-I
activity were concentrated to ;1 ml by spinning through an Ultra-
free-15 filter unit with a Biomax-30 membrane (Millipore). The sample
was then run on a Sephacryl S-300 column (1.6 3 90 cm) with buffer A,
pH 7.0, containing 100 mM KCl. The fractions with cN-I activity were
dialyzed overnight against buffer A containing 50% glycerol, and bovine
serum albumin was added to a final concentration of 2 mg/ml. Aliquots
of enzyme were stored at 280 °C until use.
Enzyme Kinetics
Radiochemical Assay and Estimation of Kinetic Parameters—En-
zyme assays were performed in 50 mM Tris, pH 7.0, 100 mM KCl, 5 mM
MgCl2, 5 mM b-glycerophosphate, 1 mg/ml bovine serum albumin, 100
mM AMPCP, and 1 mM ADP, with various concentrations of substrate.
When AMP and IMP were used as substrates, 22 nCi of 14C-labeled
compounds were used in a 20-ml reaction volume. Alternatively, 14C-
labeled dCMP was used in an amount of 5.5 nCi in a 20-ml reaction
volume. Enzyme concentrations were 69 pg/ml when assayed with
dCMP, 552 pg/ml when assayed with AMP and 1.38 ng/ml when assayed
with IMP. Enzymatic reactions were initiated by the addition of en-
zyme, run at 37 °C, and stopped by heating at 85 °C for 2 min. Reaction
rates were determined to be linear within the protein concentrations
and incubation times used. Fifteen ml of each sample was spotted onto
cellulose chromatography sheets with fluorescent indicators (Ko-
dachrome, Eastman Kodak Co. and Analtech, Newark, DE), and thin
layer chromatography was performed in a solvent containing 60% bu-
tanol, 20% methanol, 19% dH2O, and 1% ammonia. Bands were visu-
alized under UV light, and spots corresponding to the nucleoside prod-
ucts were cut out and counted on a Packard scintillation counter.
Specific activity was expressed as mmol/min/mg of substrate. The sub-
strate saturation curves were obtained within 5 mM to 60 mM concen-
trations, and the effect of ADP, ATP, and GTP (activator saturation
curves) was tested within concentrations ranging from 20 mM to 4 mM.
Data was graphed using SigmaPlot 2000 (SPSS, Inc., Chicago, IL), and
kinetic parameters were derived using either nonlinear regression
(three parametric Hill equation) or linear regression (Hanes equation)
procedures as previously described (10, 21).
Colorimetric Assay and Estimation of Substrate Specificity—Colori-
metric assays were performed in 50 mM Tris, pH 7.0, buffer containing
100 mM KCl, 5 mM MgCl2, 1 mg/ml bovine serum albumin, 100 mM
AMPCP, 1 mM ADP, and 5 mM each substrate. cN-I (34.5 ng/reaction)
was incubated in 50 ml final volume for 10 min at 37 °C. The reaction
was stopped with the addition of 1 ml of Chen reagent as previously
described (22). With F-AraAMP and AraCMP, incubation time was
increased to 40 min, and the concentration of cN-I was 10 times higher.
For the inhibition experiments, the buffer included 5 mM AMP and 1
mM competing nucleoside analog monophosphate with a 10 min incu-
bation and 34.5 ng of cN-I.
Cell Culture
Sf9 cells were maintained in Grace’s insect medium (Life Technolo-
gies) supplemented with 10% fetal bovine serum (Sigma) and 1.8 mM
L-glutamine (Life Technologies). HEK 293 cells were grown in Dulbec-
co’s modified Eagle’s medium (Life Technologies) supplemented with
10% fetal bovine serum, and Jurkat cells were maintained in RPMI
1640 medium (Life Technologies) supplemented with 10% fetal bovine
serum. All media was supplemented with penicillin and streptomycin
(Lineberger Cancer Research Center Tissue Culture Facility, Univer-
sity of North Carolina). Transfected HEK 293 and Jurkat E6–1 cells
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were maintained in the presence of G418 (Life Technologies).
Development of Stable Cell Lines
The cN-I cDNA was subcloned into the pcDNA3 mammalian expres-
sion vector that contains a pCMV promoter (Invitrogen, Carlsbad, CA).
HEK 293 cells were transfected using Fugene6 (Roche Molecular Bio-
chemicals), and Jurkat E6–1 cells were transfected by electroporation
using a Bio-Rad Gene Pulser. The transfected cells were selected in
increasing concentrations of G418, up to 750 mg/ml for HEK 293 cells
and up to 1 mg/ml for Jurkat cells. An empty pcDNA3 vector was used
as a control for both cell lines. Individual clones were selected by serial
dilution of cells transfected with the cN-I construct in 96-well plates.
Colonies grown from single cells were tested to determine cN-I activity,
and cells were maintained in the presence of G418. Due to low trans-
fection efficiency, the Jurkat cells were pre-selected with 0.5 mM CdA for
2 days before the serial dilutions.
Generation of Polyclonal Antibody and Western Blot Procedure
A synthetic acetylated peptide corresponding to the C-terminal 16
amino acids of cN-I (acetyl-CQTPRRTAPAKQAPSAQ-OH) was synthe-
sized and conjugated to keyhole limpet hemocyanin at the peptide
synthesis facility at University of North Carolina. The peptide was used
to produce rabbit polyclonal antisera to cN-I by Rockland Immuno-
chemicals (Gilbertsville, PA). Antibody was purified on a Sulfolink
column (Pierce) coupled to the original antigen peptide conjugated to
bovine serum albumin, according to the manufacturer’s instructions.
For Western blots, proteins (50 mg) were separated on a 10% poly-
acrylamide gel and transferred to an Immobilon-P membrane (Milli-
pore). Protein concentration was measured using the Bio-Rad Protein
Assay Dye Reagent. Western blots were performed with cN-I antibody
at a dilution of 1:1000 followed by horseradish peroxide-conjugated
anti-rabbit antibody (Amersham Pharmacia Biotech) at 1:5000. Bands
were visualized using ECL (Amersham Pharmacia Biotech).
Drug Sensitivity Studies
To determine whether overexpression of cN-I affects the IC50 for
various nucleoside analogs, HEK 293 and Jurkat E6–1 parental,
pCDNA3-transfected and cN-I-transfected cells were plated in 96-well
plates at a density of 2.5 3 103 cells/well for the HEK 293 cells and 2 3
104 cells/well for the Jurkat E6–1 cells. The cells were treated with
concentrations of nucleoside analogs between 1 nM and 10 mM depend-
ing on the toxicity of the drug. Cells were incubated in 96-well plates in
the presence of drug for 4 days. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide assays were performed as previously described
(23) to determine relative cell viability, with the absorbance measured
at 595 nm.
RESULTS
Cloning of Human cN-I—A FASTA search performed with
the cDNA sequence of the pigeon cN-I enzyme (24) identified
the human cN-I gene (GenBankTM accession number:
AL035404.20). Sequence analysis identified six exons with an
open reading frame of 1107 bases localized on human chromo-
some 1 p33-p34.3. Reverse transcription-PCR using human
heart poly(A) mRNA as a template produced the expected 1107-
base pair cDNA. An A to G base change at position 1729 in the
cDNA sequence and 75,616 in the GenBankTM sequence was
found in all sequenced PCR products from several different
reactions and is therefore unlikely to be a PCR-related muta-
tion. The base change does not affect the amino acid sequence.
This sequence was scanned against the GenBankTM data base
and was significantly related to three other sequences:
(AL033526.24, a fragment of AL035404.20 containing exons
4–6 of the cN-I enzyme; AJ131243.1, Columba livia (pigeon)
mRNA for cN-I, with 82% identity to the human sequence (24);
and AB045992.1, Macaca fascicularis (macaque primate) brain
cDNA, containing a stretch of 135 amino acids that is 97%
identical to the first exon of human cN-I. The human cN-I
cDNA encodes a 368 amino acid protein of 47.7 kDa that has
83% identity to the 40-kDa protein of the cloned pigeon cN-I
enzyme.
The human cN-I amino acid sequence was scanned against
the GenBankTM data base and, in addition to pigeon cN-I, was
significantly related to Xylella fastidiosa (proteobacteria) 59-
nucleotidase F82601 (25). An alignment of the human, pigeon,
and X. fastidiosa cN-I amino acid sequences is shown in Fig. 1.
All three cN-I sequences contain a conserved classic Walker B
motif (R/K)X1–4GX2–4fXf2(D/E) (f is a hydrophobic amino
acid) (26) at amino acids 220 to 233. The Walker B motif is
found in many ATP-binding proteins and may serve as part of
the nucleotide binding pocket (26). All three cN-I sequences
FIG. 1. Alignment of human, pigeon, and X. fastidiosa cN-I amino acid sequences. Similar conserved amino acids are shaded. The
conserved Walker B and kinase 2 motifs are indicated below the alignment.
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also contain a conserved kinase-2 motif near the C terminus,
IFFDD (at amino acids 338 to 342 on the alignment). Although
the sequences of kinase-2 domains are highly variable, they
usually consist of four hydrophobic residues followed by an
aspartate that interacts with Mg21, Ca21, or other divalent
metal ions (26). Mg21 is necessary for cN-I activity (16, 18–20),
and this conserved domain may be essential for enzyme func-
tion. There are several additional putative nucleotide binding
domains that are conserved only in the human and pigeon cN-I
enzymes: two kinase-2 domains are located at amino acids
31–35 and 313–317, and a putative kinase 3a domain (26) is
located at amino acids 299–304. Three putative nucleoside
monophosphate binding motifs (NMP-2), which may bind the
pentose sugar (26), are located at amino acids 68–73, 177–182,
and 313–318 on the alignment. Neither 59-nucleotidase signa-
ture 1 nor signature 2 (PROSITE), derived from conserved
ecto-59-nucleotidase domains, was found in the cN-I sequence.
Tissue Expression—Northern blot analysis was performed on
two human tissue blots (CLONTECH) to determine the tissue-
specific expression of cN-I. Data presented in Fig. 2 show that
skeletal muscle expressed a very high level of the ;10-kilobase
cN-I transcript, whereas a lower level of expression was found
in heart, brain, and pancreas. Upon overexposure, expression
could also be seen in kidney, testis, and uterus.
Purification of Recombinant cN-I—Recombinant human
cN-I expressed in Sf9 insect cells was purified from cell super-
natants by ammonium sulfate precipitation followed by phos-
phocellulose chromatography, DEAE-Sepharose chromatogra-
phy, and gel filtration chromatography (Fig. 3). This
purification procedure yielded a protein that was ;90% pure
and had a specific activity of 14.4 mmol/min/mg when assayed
with 200 mM dCMP and 1 mM ADP.
Kinetics Parameters—The relative Vmax and apparent Km
values for AMP, dCMP, and IMP were determined in both the
presence and absence of ADP as an activator. Table I summa-
rizes the data and shows that the enzyme exhibited the highest
Vmax in the presence of AMP, followed by IMP and dCMP. On
the other hand, the highest substrate affinity was obtained for
dCMP. The high ratio of Vmax/Km for dCMP demonstrated that
it was the most efficient substrate for human recombinant
cN-I.
ADP was required for the full activity of recombinant human
cN-I. ADP both increased the Vmax and decreased the Km for all
three substrates (Table I). The Hill coefficient in the presence
of ADP was close to 1 for all three substrates, whereas in the
absence of ADP, it increased to 2.6 or 2.7 (Table I). Such kinetic
behavior suggests that ADP functions as an allosteric activator
of cN-I. When cN-I activity was measured at increasing ADP
concentrations (from 20 mM to 2 mM) and at a fixed concentra-
tion of dCMP, half-maximal activity (A0.5) was reached at a
concentration of 89 mM (Fig. 4 and Table II). The steep initial
slope of the curve indicates that ADP at concentrations below
200 mM is a critical physiological regulator of cN-I activity. GTP
also served as an activator for cN-I, although not as strong as
ADP, and there was only slight activation by ATP (Fig. 4 and
Table II).
The data in Table III summarizes the substrate specificity
with a larger range of substrates. In general, higher specific
activities were observed with purine substrates and pyrimidine
ribonucleoside monophosphates, and lower specific activities
were measured with pyrimidine deoxyribonucleoside mono-
phosphates. The nucleoside analog CdAMP was a good sub-
strate for cN-I, with a relative activity 39% that of AMP. The
other analogues used in clinic, F-AraAMP and AraCMP, were
not dephosphorylated by cN-I.
Since F-AraAMP and AraCMP appear to be poor substrates
for cN-I, we tested the possibility that they may function as
competitive inhibitors. Table IV demonstrates that, in an assay
buffer containing 5 mM AMP, cN-I activity was inhibited 70%
by 1 mM F-AraAMP and 25% by 1 mM AraCMP, indicating that
both compounds negatively affect the activity of the enzyme.
Effect of cN-I Expression on Drug Sensitivity—Clonal popu-
lations of HEK 293 cells and Jurkat E6–1 cells stably express-
ing cN-I were isolated by serial dilution. The Jurkat clone used
for this study had 7-fold higher cN-I activity (9.8 nmol/mg/min)
than parental cells, and the HEK 293 clone had 147-fold higher
cN-I activity (128 nmol/mg/min) than parental cells when ac-
tivity was measured in the presence of 200 mM dCMP and 1 mM
ADP. Under the assay conditions used, ecto-59- nucleotidase
FIG. 2. Expression of cN-I in human tissues. A, Northern blot
analysis was performed with two human tissue blots (CLONTECH
MTN 7760–1 and 7759–1). The cN-I mRNA migrates at ;10 kilobases
(kb). B, blots were reprobed with b-actin cDNA to control for loading.
PBL, peripheral blood leukocyte.
FIG. 3. Purification of recombinant human cN-I. Recombinant
human cN-I was expressed in Sf9 insect cells using Life Technologies,
Inc. baculovirus expression system. The Sf9 cells were homogenized,
and the membranes were pelleted. The supernatant was precipitated
with 40% ammonium sulfate. The sample was further purified on a
phosphocellulose column, a DEAE-Sepharose column, and a Sephacryl-
300 gel filtration column. The following amount of protein was loaded
onto each lane: supernatant, 20 mg; ammonium sulfate precipitation, 20
mg; phosphocellulose column, 10 mg; DEAE-Sepharose column, 5 mg;
and Sepharcryl-300 column, 5 mg. Protein was run on a 10% SDS-
polyacrylamide electrophoresis gel and stained with Coomassie Blue.
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and cN-II could not have contributed significantly to measured
cN-I activity. Northern and Western blot analyses showed cN-I
mRNA and protein only in the overexpressing cell lines (Fig. 5,
A and B).
HEK 293 and Jurkat E6–1 cells were treated with eight
nucleoside analogs for 4 days, and cell viability was determined
by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide assay. In the presence of CdA, overexpression of cN-I
led to a 49-fold increase in IC50 in the HEK 293 cell line and a
greater than 400-fold increase in IC50 in the Jurkat cell line
(Fig. 6 and Table V). The IC50 for the Jurkat cells expressing
cN-I was greater than 100 mM, the highest concentration used
in this assay, so the exact IC50 and fold increase due to expres-
sion of cN-I could not be determined. Both cell lines showed
smaller increases in IC50 to both AraC and F-AraA and no
change in IC50 with compound 506U (AraG prodrug) or d4T
(Table V). Overexpression of cN-I conferred a 22-fold increase
in IC50 to dFdC and a 5.2-fold increase in IC50 to 5-FU in the
HEK 293 cells and an 82-fold increase in IC50 to ddC in the
Jurkat cell line (Fig. 6 and Table V). Higher levels of cN-I in the
HEK 293 cells could not explain all the differences in drug
sensitivity because the Jurkat cells showed a larger increase in
IC50 to ddC, F-AraA, and CdA, indicating that cell type-specific
differences are also important.
DISCUSSION
Interest in cN-I and cN-II originally stemmed from research
to determine which nucleotidase was responsible for increased
adenosine formation from AMP in the heart in response to
ischemia, hypoxia, and increased workloads. During conditions
of metabolic stress, net catabolism of ATP leads to increased
ADP and AMP levels (27). Adenosine, produced by dephospho-
rylation of AMP, can help restore ATP levels by decreasing ATP
utilization and increasing blood flow and, therefore, O2 and
substrate supply to the heart (28). Adenosine also contributes
to ischemic preconditioning, a cardioprotective mechanism that
can prevent damage from a longer period of ischemia (29). The
kinetic characteristics of cN-I and cN-II have been studied to
determine the contribution of each enzyme to this process.
From the characteristics of the purified cN-I enzyme and the
TABLE I
Substrate specificity of recombinant human cN-I
The Vmax and apparent Km of cN-I for AMP, IMP, and dCMP were determined by varying the concentration of substrate both in the presence
and absence of ADP as an activator. The Vmax, apparent Km, and Hill coefficients were calculated using non-linear regression (10, 21). Experimental




Apparent Km Vmax/Km Hill coefficient
mM mmol/mg/min % mM
AMP 1* 364.5 6 17.1 100 1.87 6 0.23 53 1.25 6 0.13
0 7.7 6 0.8 2 2.96 6 0.07 2.62 6 0.46
dCMP 1 49.5 6 0.1 14 0.012 6 0.001 1133 1.40 6 0.01
0 18.1 6 0.6 5 0.193 6 0.008 2.74 6 0.06
IMP 1* 155.0 6 11.0 43 2.47 6 0.62 17 1.00 6 0.10
0 33.2 6 2.6 9 12.11 6 1.00 2.69 6 0.18
FIG. 4. The effects of ADP, ATP and GTP concentration on the
activity of cN-I. cN-I specific activity was measured at varying con-
centrations of ADP (l), ATP (E), and GTP () and at a fixed concen-
tration (20 mM) of dCMP substrate. Representative plots are shown.
TABLE II
Activation of cN-I by ADP, ATP, and GTP
The specific activity of cN-I was measured at varying concentrations
of ADP, ATP, and GTP and a fixed concentration (20 mM) of dCMP
substrate. The Vmax and A0.5 were calculated using linear regression




ADP 40.6 6 3.6 89 6 11
ATP 5.6 6 0.5 122 6 14
GTP 15.1 6 1.5 33 6 1
TABLE III
Substrate specificity of recombinant human cN-I
Phosphate generation by cN-I was measured for each nucleoside
monophosphate shown using Chen reagent (22). Specific activity was
calculated in mmol of phosphate generated/min/mg of cN-I protein 6
S.D. for three experiments. All substrate concentrations were 5 mM.
Substrate Specific activity Relative activity
mmol/mg/min % AMP
AMP 122 6 3 100
dAMP 111 6 15 91
CMP 104 6 10 85
dIMP 102 6 11 84
UMP 95 6 12 78
dGMP 92 6 13 75
IMP 75 6 6 61
GMP 70 6 10 57
CdAMP 48 6 11 39
TMP 16 6 4 13
dCMP 12 6 1 10




Inhibition of AMP dephosphorylation by F-AraAMP and AraCMP
Phosphate generation was measured using 5 mM AMP as a substrate
and 1 mM of competitor. Specific activity represents the mean 6 S.D. for
three assays.
Competitor Specific activity % Inhibition
mmol/mg/min
None 121 6 6
F-AraAMP 36 6 2 70
AraCMP 91 6 2 25
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cloned pigeon cN-I enzyme, cN-I has been identified as the
enzyme responsible for most of the adenosine production in
hypoxic and ischemic heart tissue (15, 19, 24, 30).
Although cN-I has been purified and characterized from rab-
bit, rat, pigeon, dog, and human hearts, there is only limited
information on its role in pyrimidine metabolism (17, 20). As
has been shown for the purified cN-I enzymes, recombinant
human cN-I showed the highest specific activity with AMP as a
substrate. In addition, the recombinant enzyme showed high
relative activity with all naturally occurring nucleoside mono-
phosphates except the pyrimidine dexoyribonucleoside mono-
phosphates. These results are consistent with those obtained
for the pigeon enzyme (20), and although the relative activities
are slightly higher for the human enzyme, the order of relative
catalytic rate is nearly identical. Although the enzyme had a
lower specific activity with pyrimidine deoxyribonucleoside
monophosphates, when catalytic efficiency was assessed by the
Vmax/Km ratio, dCMP was 21 times more efficient as a sub-
strate than AMP. Similar results were reported for the rabbit
cN-I enzyme (17). Although the Km values for TMP and dUMP
were not determined, based on the rabbit enzyme data they are
also likely to be efficient substrates of cN-I. Thus, dCMP and
other pyrimidine deoxyribonucleoside monophosphates are
likely to be important physiological substrates of human cN-I.
Our study demonstrates that ADP is a critical regulator of
cN-I activity, and this feature is compatible with an important
role of this enzyme in adenosine generation in the heart during
ischemia (30). Interestingly, the activation of recombinant hu-
man cN-I by ADP was 6–20 times stronger than for the cN-I
purified from pigeon, rabbit, or dog hearts (16, 18, 20). This
striking difference may reflect species differences or result
from either copurification of an activator (ADP or GTP) or from
a potential posttranslational modification of a native protein
that renders cN-I less dependent on ADP. Our data suggest
that ADP is a key regulator of human cN-I within the range of
10–200 mM. ADP levels in guinea pig heart increase from 38 mM
to 72 mM under conditions of mild hypoxia and to 238 mM under
conditions of severe hypoxia (31). In rat heart, control ADP
FIG. 5. Expression of cN-I in stably transfected cell lines. HEK
293 and Jurkat E6–1 cells were stably transfected with the cN-I con-
struct in a pcDNA3 vector, and clonal cell lines were obtained for each.
A, Northern blot analysis with cN-I cDNA (top) and ethidium bromide-
stained membrane showing 28 S rRNA (bottom). B, Western blot anal-
ysis with anti-cN-I antibody.
FIG. 6. Drug resistance in cell lines stably expressing cN-I.
Parental, pcDNA3-transfected, and cN-I transfected HEK 293 and Ju-
rkat E6–1 cell lines were treated with nucleoside analogs for 4 days.
Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide assays and compared with control cells that did
not receive nucleoside analog treatment. Representative graphs are
shown from single experiments done with nine replicates with parental
(l), vector-transfected (E), and cN-I-transfected () cells.
TABLE V
Fold increase in IC50 of nucleoside analogs in two cell lines
overexpressing cN-I
HEK 293 and Jurkat cell lines were treated with varying concentra-
tions of nucleoside analogs for 4 days. Percent cell viability was calcu-
lated compared with control cells that did not receive nucleoside analog
treatment. The IC50 values were calculated from graphs of the data. The
average fold increase in IC50 6 S.E. due to expression of cN-I is shown
for two or three (*) experiments, each containing nine replicate platings.
All values represent the fold increase compared with parental cells
unless otherwise indicated (‡), because transfection with empty vector
slightly increased the sensitivity of the cells to nucleoside analogs.
Hence, a comparison of the cN-I-transfected cells to vector-transfected
cells might overestimate the increase in IC50.
Drug HEK 293 Jurkat
AraC 3.7 6 1.3 2.7 6 0.3
CdA 49.3 6 16.8* .446.4
dFdC 21.6 6 6.3 1.3 6 0.0
F-AraA 2.3 6 0.2 8.0 6 3.0
ddC 3.7 6 0.4 81.6 6 43.0*
5-FU 5.2 6 1.6 0.7 6 0.1*‡
506U (AraG) 0.7 6 0.3‡ 1.6 6 0.6*
d4T 1.0 6 0.0 1.0 6 0.0
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concentrations of 64 mM increase to 106 mM under hypoxic
conditions (32). These fluctuations in ADP levels are precisely
within the range of A0.5 value for this activator and further
signify the important role of this enzyme in adenosine genera-
tion in the heart during ischemia (15, 17, 24) and potentially
also in working skeletal muscle. Interestingly, recombinant
human cN-I is also significantly activated by GTP, and an
increase in GTP levels, for example during cellular prolifera-
tion, may also play a role in activation of the enzyme.
The data presented in Table V show that increased activity of
cN-I can lead to resistance to several nucleoside analogs, in-
cluding CdA, dFdC, and ddC, and to a smaller extent, to 5-FU,
AraC, and F-AraA. The change in IC50 values for these com-
pounds in the presence of cN-I seems to correlate with the in
vitro activity of cN-I with CdAMP, F-AraAMP, and AraCMP
(Tables III and IV). Thus, the relatively high activity with
CdAMP leads to strong resistance to CdA in cells overexpress-
ing cN-I and the lack of in vitro activity with either F-AraAMP
or AraCMP correlates with a much smaller increase in resist-
ance to the respective nucleosides. Unfortunately, we were not
able to extend this comparison to other nucleoside monophos-
phates since they are not commercially available.
The strong dependence of cN-I activity on increased ADP
concentrations may also be relevant to resistance to nucleoside
analogs in tumors that experience hypoxia. Hypoxic tumors
have poorer clinical prognosis, are often resistant to both radi-
ation and chemotherapy (33), and are more likely to metasta-
size (34). The nucleoside analogs 5-FU and dFdC are used
clinically in the treatment of solid tumors (35, 36), and we have
shown that elevated expression of cN-I increases the IC50 for
5-FU 5.2-fold and the IC50 for dFdC 21.6-fold in the HEK cells
(Table V). Although the effect of hypoxia on drug resistance in
the context of cN-I activity remains to be investigated, this
study provides support for the hypothesis that increased ADP
concentrations in ischemic tumors may facilitate dephospho-
rylation of several nucleoside-based drugs and lower their
pharmacological efficacy.
Although cN-I was not detected in peripheral blood leuko-
cytes (Fig. 2), aberrant expression in malignant cells or en-
hanced expression as a result of prior chemotherapy exposure
could play a role in resistance to nucleoside analogs in leuke-
mias and lymphomas, where these drugs are extensively used.
Future studies will determine whether cN-I levels are in-
creased in leukemic cells from patients who are resistant to
nucleoside analog therapy.
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